Therapix Biosciences Reports Third Quarter 2017 Financial Results and Provides Business Update - Conference Call and Webcast Today at 8:30 a.m. EDT / 5:30 a.m. PDT

Biosciences Reports Third Quarter 2017 Financial Results and Provides Business Update

Conference Call and Webcast Today at 8:30 a.m. EDT / 5:30 a.m. PDT -

AVIV, Israel, November 9, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical-stage pharmaceutical

company specializing in the development of cannabinoid-based treatments, today reported financial results for the three and nine

months ended September 30, 2017. The Company will host a conference call and webcast today to discuss the financial results and

to provide an update on current developments with respect to its clinical programs.

Summary - Third quarter 2017 vs. third quarter 2016 (Note: The functional currency of the Company is New Israeli Shekel;

for presentation purposes, the financial data herein is presented in USD):

update and developments in the Company's clinical R&D programs:

Cognitive Impairment ("MCI"):

November 09, 2017, 8:30 am Eastern Time / 5:30 am Pacific Time

available until Nov. 16, 2017

Table 1: Balance Sheet [based on an effective exchange rate of 3.529 NIS/USD for September 30, 2017]:

Table 2: Profit or Loss [based on an effective exchange rate of 3.563 NIS/USD

for the quarter ended September 30, 2017]:

Table 3: Comprehensive Income [based on an effective exchange rate of 3.563 NIS/USD

for the quarter ended September 30, 2017]:

Table 4: Cash Flows [based on an effective exchange rate of 3.563 NIS/USD for

the quarter ended September 30, 2017]:

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

Table 5: Changes in Equity [based on an effective exchange

rate of 3.529 NIS/USD for September 30, 2017]:

Table 6: R&D and G&A Detail [based on an effective

exchange rate of 3.563 NIS/USD for the quarter ended September 30, 2017]:

Therapix Biosciences Ltd.:

Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists.

Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus,

the Company is currently engaged in the following drug development programs based on repurposing an FDA approved synthetic cannabinoid

(dronabinol): THX-110 and THX-120 for the treatment of Tourette syndrome (TS) and Obstructive Sleep Apnea (OSA); THX-130 for the

treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); and THX-150 for the treatment of infectious diseases.

Please visit our website for more information at www.therapixbio.com.

TXH-110 (Previously referred to as THX-TS01 and THX-OSA01):

is a combination drug candidate for the treatment of Tourette syndrome and Obstructive Sleep Apnea. It is based on two components:

(1) dronabinol (an FDA approved synthetic analog of 9-tetrahydracannabinol, or "THC"), which is the psychoactive

molecule in the cannabis plant, and (2) palmitoylethanolamide ("PEA"), which is an endogenous fatty acid amide that

belongs to the class of nuclear factor agonists, which are proteins that regulate the expression of genes. The combination of

THC and PEA may induce a reaction known as the "entourage effect." The basic tenet of the entourage effect is that cannabinoids

work together, or possess synergy, and affect the body in a mechanism similar to the body's own endocannabinoid system, which

is a group of molecules and receptors in the brain that mediates the psychoactive effects of cannabis. This entourage effect may

account for the pharmacological actions of PEA. Based on an activity enhancement of other physiological compounds, PEA may indirectly

stimulate the cannabinoid receptors by potentiating their affinity for a receptor or by inhibiting their metabolic degradation,

and by doing so, may increase the uptake of cannabinoid compounds, such as THC. Thus, it is speculated that the presence of the

PEA molecule could increase the efficacy of orally administered THC, while reducing the required dosage and decreasing associated

deleterious adverse events.

a first-in-class, proprietary investigational drug candidate for the treatment of Tourette syndrome. THX-120 contains the two

active ingredients, THC and PEA in a single pill.

THX-130 (Previously referred to as THX-ULD01):

is a proprietary, new, ultra-low dose formulation of dronabinol, which is intended to provide a treatment for Mild Cognitive Impairment

(MCI). TXH-130 is being developed to be delivered either by sublingual or nasal administration. Recent pre-clinical animal studies

have found that an ultra-low dose of THC could potentially protect the brain from long-term cognitive impairment, which may be

caused by lack of oxygen supply, seizures or use of drugs. Certain pre-clinical studies also suggest that ultra-low doses of THC

cause animals to improve performance in behavioral tests that measure learning and memory.

is a drug candidate intended for the treatment of infectious diseases. It consists of dronabinol and/or palmitoylethanolamide

(PEA) and selected antibacterial agent and possesses antimicrobial synergy potential.

syndrome is a neuropsychiatric disorder, characterized by physical (motor) tics and vocal (phonic) tics. Motor or phonic tics

are sudden, brief, intermittent, involuntary or semi-voluntary movements or sounds, respectively. They typically consist of brief,

coordinated, repetitive movements, gestures, or utterances that mimic fragments of normal behavior. The tics associated with Tourette

syndrome can have significant effects on the academic and social development of children as well as affecting their overall self-esteem

and mental health. Although the majority of children experience a decrease in their tics during adolescence, the worst symptoms

are usually experienced by adults with intractable Tourette syndrome.

Obstructive Sleep Apnea:

to the Mayo Clinic, obstructive sleep apnea, or OCA, is a potentially serious sleep disorder. It causes breathing to repeatedly

stop and start during sleep. There are several types of sleep apnea, but the most common is obstructive sleep apnea. This type

of apnea occurs when your throat muscles intermittently relax and block your airway during sleep. A noticeable sign of obstructive

sleep apnea is snoring. OSA affects 29.4 million American men and women, which represents 12 percent of the U.S. adult population,

according to The American Academy of Sleep Medicine (AASM) and Frost & Sullivan.

Mild Cognitive Impairment:

cognitive impairment ("MCI") is an intermediate stage between the expected cognitive decline of normal aging and the

more-serious decline of dementia. It can involve problems with memory, language, thinking and judgment that are greater than normal

age-related changes. MCI causes cognitive changes that are serious enough to be noticed by the individuals experiencing them,

or to other people, but the changes are not severe enough to interfere with daily life or independent function. People with MCI,

especially those involving memory problems, are more likely to develop Alzheimer's disease or other dementias than people without

MCI. MCI is a widespread condition that increases with age at a rate of 10% among 70-79-year-olds and 25% among 80-89-year-olds.

There is currently no FDA approved treatment for MCI.

Antimicrobial Resistance:

to the World Health Organization, antimicrobial resistance, classified as a 'serious threat', occurs when microorganisms are exposed

to antimicrobial drugs. As a result, medicines become ineffective and infections persist, increasing the risk of spread. New resistance

mechanisms are emerging globally, threatening the ability to treat common infectious diseases. Without effective antimicrobials

for prevention and treatment of infections, medical procedures such as organ transplantation, cancer chemotherapy, diabetes management

and major surgery are jeopardized. Antimicrobial resistance increases the cost of healthcare with lengthier stays in hospitals

and more intensive care required.

to the U.S. Centers for Disease Control and Prevention in conjunction with research conducted at Tufts University, antibiotic-resistant

infections add considerable and avoidable costs to the already overburdened U.S. healthcare system. In most cases, antibiotic-resistant

infections require prolonged and/or costlier treatments, extend hospital stays, necessitate additional doctor visits and healthcare

use, and result in greater disability and death compared with infections that are easily treatable with antibiotics.

press release contains forward-looking statements about the Company's expectations, beliefs, and intentions. Forward-looking statements

can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan",

"may", "should", "could", "might", "seek", "target", "will",

"project", "forecast", "continue" or "anticipate" or their negatives or variations of

these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. Such

forward-looking statements used in this press release include, among other things, references to the clinical and commercial potential